WASHINGTON, D.C. — The U.S. Food and Drug Administration has launched a new centralized system that will allow scientists, regulators, and the public to analyze safety reports for drugs, vaccines, medical products, and other regulated items through a single platform.
What This Means for You
- Safety reports for drugs, vaccines, cosmetics, and other products will be available through one system.
- The platform will publish adverse event reports in real time rather than quarterly.
- The FDA expects the modernization effort to save about $120 million over five years.
The new platform, called the FDA Adverse Event Monitoring System, is designed to consolidate several existing reporting systems that track adverse events — unexpected or harmful reactions linked to medical products and other regulated goods.
The system is available online at https://www.fda.gov/safety/fda-adverse-event-monitoring-system-aems.
Modernizing Safety Monitoring
Adverse event reports are submitted by patients, health care providers, manufacturers, and consumers to alert regulators about possible safety problems linked to medications, vaccines, and other products.
These reports help regulators identify potential safety signals — patterns of health problems that could indicate previously unknown risks associated with a product.
FDA Commissioner Dr. Marty Makary said the agency’s previous systems were outdated and difficult to use.
“The FDA’s previous adverse event reporting systems were outdated and fragmented and made important data difficult to access,” Makary said. “Starting today, the FDA will have a single, intuitive adverse event platform that will better serve agency scientists, researchers, and the public.”
Replacing Multiple Legacy Systems
In the past, the FDA processed roughly 6 million adverse event reports each year through seven separate databases.
Those systems collectively cost about $37 million annually to operate and often required users to search multiple platforms to access relevant data.
The new system consolidates those reporting tools into a single dashboard that displays safety reports across several product categories.
Legacy systems being replaced include the FDA Adverse Event Reporting System for drugs and biologics, the Vaccine Adverse Event Reporting System for vaccines, and reporting systems used to track animal drug and animal food safety issues.
Additional Databases to Be Added
By the end of May 2026, the FDA plans to integrate additional reporting databases into the system.
These include systems that track adverse events related to medical devices, human foods and dietary supplements, and tobacco products such as electronic nicotine delivery systems.
The agency said historical adverse event data will also be migrated into the new system.
Real-Time Data Access
Unlike previous systems that released data periodically, the new platform will publish adverse event reports in real time.
FDA officials said the increased transparency may also reduce the number of Freedom of Information Act requests seeking access to safety data.
Chief AI Officer Jeremy Walsh said consolidating the agency’s reporting systems required a major technical overhaul.
“Consolidating the FDA’s adverse event systems and converting to real-time publication was challenging, but made possible by a highly aggressive schedule,” Walsh said.
Privacy Protections
The FDA said the new platform will continue to protect patient and consumer privacy.
Although safety reports will be publicly available, the system will not release personally identifiable information tied to patients or consumers.
Officials said the platform represents a major step in modernizing how the agency monitors the safety of products after they reach the market.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.